Skip to main content

Table 2 The lung status of SARS survivors assessed by mMRC score, pulmonary function tests, and chest CT

From: Investigation of the impact of SARS-CoV infection on the immunologic status and lung function after 15 years

  The severe group The non-severe group F/T P
mMRC scorea N = 22 N = 34   
 0 5 (22.7%) 11 (32.4%) 4.785 0.310
 1 11 (50.0%) 12 (35.3%)   
 2 3 (13.6%) 10 (29.4%)   
 3 3 (13.6%) 1 (2.9%)   
Pulmonary function parametersb N = 21 N = 31   
 FVC (L) 3.10 ± 0.59 3.52 ± 0.6 − 2.517 0.015
 FVC (%) 101.41 ± 14.52 104.69 ± 13.30 0.835 0.408
 FVC% < 80% 0 0
 FEV1(L) 2.48 ± 0.514 2.90 ± 0.453 3.313 0.003
 FEV1 (%) 95.21 ± 12.46 101.61 ± 12.66 1.604 0.108
 FEV1% < 80% 4 (19.0%) 0 6.397 0.011
 FEV1/FVC (%) 79.23 ± 4.35 82.64 ± 4.80 2.611 0.012
 FEV1/FVC < 70% 1 (4.8%) 0 1.505 0.220
 DLCO (mmol/min/KPa) 6.86 ± 1.31 7.18 ± 1.43 0.807 0.424
 DLCO (%) 84.01 ± 11.06 82.18 ± 12.42 − 0.563 0.576
 DLCO% < 80% 6 (28.6%) 13 (41.9%) 0.964 0.326
 TLC (L) 5.05 ± 0.87 5.39 ± 0.71 1.599 0.116
 TLC (%) 100.32 ± 10.83 103.93 ± 9.37 1.277 0.207
 TLC% < 80% 0 0
 RV/TLC (%) 38.69 ± 5.86 37.23 ± 5.77 − 0.889 0.378
 RV (%) 107.73 ± 13.66 111.70 ± 17.22 0.884 0.381
 RV% > 120% 6 (28.6%) 12 (38.7%) 0.569 0.451
 FEF25–75 (%) 65.95 ± 19.73 82.69 ± 20.36 2.946 0.005
 FEF25–75% < 65% 12 (57.1%) 7 (22.6%) 6.449 0.011
CT abnormalitiesc N = 22 N = 33   
 GGO 6 (27.3%) 2 (6.0%) 16.360 < 0.001
 Interstitial fibrosis 7 (31.8%) 0   
 Others 5 (22.7%) 1 (3.0%)   
  1. a, b, c, The number of SARS survivors undertaking different tests